IPHA (Innate Pharma) Intangible Assets: $0.00 Mil (As of Dec. 2025)


IPHA Innate Pharma SA IPHA
39 GF Score
Price $1.90
GF Value $0.16
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Innate Pharma Intangible Assets?

Innate Pharma IPHA +1.60% 39 Intangible Assets is $0.00 Mil as of Dec. 2025. GuruFocus rates IPHA with a GF Score™ of 39/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Innate Pharma's intangible assets for the quarter that ended in Dec. 2025 was $0.00 Mil.

Innate Pharma  (NAS:IPHA) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.

Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.

Innate Pharma Intangible Assets Related Terms

Innate Pharma Intangible Assets Historical Data

* Premium members only.

The historical data trend for Innate Pharma's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innate Pharma Intangible Assets Chart

Innate Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.93 1.65 0.45 0.00 0.00

Innate Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.13 0.00 0.00 0.00
IPHA
39GF Score
Innate Pharma SA IPHA
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innate Pharma Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of $0.00 Mil mean?
Innate Pharma (IPHA) has a Intangible Assets of $0.00 Mil as of Dec. 2025. Intangible assets include patents, goodwill and trade secrets. View historical data on Innate Pharma and its competitors.
Is Innate Pharma's Intangible Assets too high?
Innate Pharma's current Intangible Assets is $0.00 Mil. Overall, Innate Pharma has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Intangible Assets compare to VRTX and REGN?
Innate Pharma's Intangible Assets of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Biotechnology company?
A good Intangible Assets depends on the Biotechnology industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Innate Pharma and its competitors. Innate Pharma's current Intangible Assets is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.90 — trading 1087.4% above its estimated fair value. The current Intangible Assets is $0.00 Mil. Innate Pharma's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Intangible Assets is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innate Pharma (IPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of $1.90 is trading 1087.4% above its estimated GF Value™ of $0.16. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for IPHA:

  • Intangible Assets: $0.00 Mil
  • GF Value™: $0.16 vs. price of $1.90 (1087.4% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
39GF Score

Get the complete analysis for IPHA

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.90
Price
$0.16
GF Value